A Systematic Review of Stem Cell Secretome-Derived Exosomes for Neuropathic Pain: Therapeutic Mechanisms and Translational Potential.
Aidin Shahrezaei, Lili Dashti, Farinaz Nasirinezhad
✦ AI-curated · Sources linked
In 30 seconds
This systematic review assessed the therapeutic mechanisms and potential of stem cell secretome-derived exosomes for neuropathic pain (NP) in preclinical and clinical studies. Seventeen studies were included, primarily focusing on mesenchymal stem cell exosomes, which showed reductions in pain-related behaviors. The pilot clinical study indicated a favorable safety profile, but human evidence is insufficient to confirm clinical efficacy.
Key findings
- Seventeen studies were included, comprising 16 preclinical and one pilot clinical study.
- Exosomes demonstrated reductions in pain-related behaviors in various NP models.
- Therapeutic effects were linked to suppression of neuroinflammatory cytokines and microglial activation.
- The pilot clinical study suggested a favorable safety profile for exosome therapy.
Why it matters
Neuropathic pain is challenging to manage, and current therapies are often inadequate. Understanding the potential of stem cell secretome-derived exosomes could lead to novel therapeutic strategies that address underlying mechanisms of NP.
What to keep in mind
The review noted substantial heterogeneity in study methodologies, including variations in stem cell sources and exosome isolation methods, which limited the ability to perform a meta-analysis.